La Jolla Cancer Research Foundation

Neurogenetic Pharmaceuticals, Inc.

Syntex (u.s.a.) Inc.

University of California

The General Hospital Corporation

Calcimedica, Inc.

Other

Syngenta Crop Protection, Inc.

Torreypines Therapeutics, Inc.

Dupont Pharmaceuticals Research Laboratories, Inc.

Massachusetts General Hospital Corporation

Tanzi, Rudolph E.

Soan Cheng

Juerg F Tschopp

William S Craig

Michael D Pierschbacher

Daniel G Mullen

Ronald Ingram

David S Lukeman

Long Mao

Guity P Balow

Daniel D Comer

David Pleynet

Eric Brian Sjogren

David Michael Goldstein

Teresa Alejandra Trejo Martin

Jeffrey Paul Whitten

Rudolph Emile Tanzi

Gonul Velicelebi

Kenneth Stauderman

William C Mobley

Steven L Wagner

David P M Pleynet

Dale L Boger

Peter Grootenhuis

Martin Zeller

Martin Eberle

Gerald Wayne Craig

James W Polarek

Lin-Shu Liu

Peter L Myers

John Saunders

James R Glass

Steven Scott Bondy

Kenneth T Dickerson

Daniel Dennis Comer

Julie Elizabeth Penzotti

Jürg Ehrler

There are provided, inner alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.

Gamma-secretase modulators

The invention provides a novel compound having a structure corresponding to Formula (I):(A)-(B)-(C)-(D)&#x2003;&#x2003;(I)or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.

Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms

Described herein are compounds and pharmaceutical compositions containing compounds of Formula (I), which modulate the activity of store-operated calcium (SOC) channels: wherein R, Rand Rare defined herein. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

Compounds that modulate intracellular calcium

Described herein are compounds of Formula I and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also describe herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

Novel compounds, compositions, and kits are provided. Methods of modulating A&#x3b2; levels, and methods of treating a disease associated with aberrant A&#x3b2; levels are also provided.

&#x3b1;-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom

Compounds and uses thereof in modulating amyloid &#x3b2;

Compounds and uses thereof in modulating amyloid beta

Compounds of general formula (I) wherein the substituents are as defined in claimare suitable for use as herbicides

Organic compounds

p38 map kinase inhibitors

The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic amino acids adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic amino acid an adjacent positively charged amino acid. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.

Method and composition for treating thrombosis

p38 MAP kinase inhibitors

The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic. moiety an adjacent positively charged moiety. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.

The present invention relates to compounds of Formula (I)

P38 MAP kinase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Soan Cheng